Found 765 clinical trials
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
body. MF disturbs the body's normal production of blood cells, causing extensive scarring in the bone marrow. This leads to severe anemia, weakness, fatigue, and an enlarged spleen. The purpose of
- 226 views
- 29 Apr, 2021
- 225 locations
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis
body's normal production of blood cells. It causes bone marrow scarring, leading to severe anemia that can cause weakness and fatigue. It can also cause a low number of blood-clotting cells called
- 80 views
- 29 Apr, 2021
- 149 locations
A Phase 2, Open-Label Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia
The purpose of this study is to evaluate the safety and efficacy of INCB050465 administered orally to participants with autoimmune hemolytic anemia (AIHA) who have decreased hemoglobin and
- 68 views
- 25 Aug, 2021
- 1 location
TRANSCEND - Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) - TRANSCEND-CLL-004 - US Spanish
Phase 2 single-arm, multi-cohort study to determine the efficacy and safety of JCAR017 (autologous T cells expressing anti-CD19 chimeric antigen receptor) in adult subjects with aggressive B-NHL (diffuse large B-cell lymphoma (DLBCL) NOS [de novo or transformed follicular lymphoma (tFL)], double/triple-hit lymphoma [DHL/THL], follicular lymphoma Grade 3B [FL3B], primary central …
- 300 views
- 26 Mar, 2021
- 16 locations
Eltrombopag for People With Fanconi Anemia
Fanconi anemia is a genetic disease. Some people with it have reduced blood cell counts. This means their bone marrow no longer works properly. These people may need blood transfusions for anemia
- 91 views
- 22 Dec, 2020
- 1 location
Eltrombopag Added to Standard Immunosuppression in Treatment-Naive Severe Aplastic Anemia
Background: Severe aplastic anemia is a rare and serious blood disorder. It happens when the immune system starts to attack the bone marrow cells. This causes the
- 123 views
- 22 Dec, 2020
- 1 location
COMMANDS - Myelodysplastic Syndromes (MDS) - ACE536-MDS-002 - Australia
) versus epoetin alfa for the treatment of anemia due to IPSS-R very low, low or intermediate risk MDS in ESA naïve subjects who require RBC transfusions. The study is divided into the Screening
- 406 views
- 06 Aug, 2021
- 7 locations
COMMANDS - Myelodysplastic Syndromes (MDS) - ACE536-MDS-002 – Canada
safety of luspatercept (ACE-536) versus epoetin alfa for the treatment of anemia due to IPSS-R very low, low or intermediate risk MDS in ESA naïve subjects who require RBC transfusions.  
- 498 views
- 03 Aug, 2021
- 10 locations
COMMANDS - Myelodysplastic Syndromes (MDS) - ACE536-MDS-002 - US
luspatercept (ACE-536) versus epoetin alfa for the treatment of anemia due to IPSS-R very low, low or intermediate risk MDS in ESA naïve subjects who require RBC transfusions. The
- 5438 views
- 01 Sep, 2021
- 9 locations